

hu



Huons

Business Performance

4Q. 2025



Huons

Disclaimer

Information in this book, including business performance and financial statements, is written following Korean-International Financial Reporting Standards(K-IFRS).

This book contains “forward-looking statements” about future events. It includes management’s expectations of future events and financial performance, and words such as ‘anticipation’, ‘forecast’, ‘plan’, ‘expectation’, and ‘(E)’.

A “forecast” can mean uncertain factors which can affect the company either positively or adversely, and those can include:


- Domestic or international financial market trends including fluctuation of foreign exchange rate or interest rate
- Company’s very important strategic decision such as M&A
- Unexpected change in business environment of the company’s core industry
- Other internal or external change that may affect the company’s management and finance

The information in this book is written as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. It can be changed without any prior notice in the future.

"2025 consolidated Sales of KRW 620.8 billion and operating profit of KRW 45.6 billion"

- Full-year Sales grew 5.2% and operating profit 14.9%, driven by export growth and SG&A cost control
- Q4 Sales Reaches All-Time Quarterly High; Operating Income Pressured by Rising Cost Ratio and Intangible Asset Amortization

Quarterly Consolidated P&L



Annual Consolidated P&L

[Unit: billion KRW, %]

	2024		2025		YoY	
	4Q	Cumulative	4Q	Cumulative	4Q	Cumulative
Sales	146.6	590.2	165.2	620.8	+ 12.7%	+ 5.2%
Cost of Sales (%)	77.0 (52.5%)	305.0 (51.7%)	95.6 (57.9%)	338.6 (54.5%)	+ 5.4%p	+ 2.9%p
SG&A (%)	58.7 (40.0%)	245.5 (41.6%)	59.7 (36.2%)	236.6 (38.1%)	- 3.8%p	- 3.6%p
OP (%)	11.0 (7.7%)	39.7 (6.7%)	9.8 (6.0%)	45.6 (7.3%)	- 10.6%	+ 14.9%
NP (%)	3.9 (5.5%)	29.1 (4.9%)	9.2 (6.9%)	43.8 (7.1%)	+135.0%	+ 43.2%

"Subsidiaries Turn Profitable on Steady Sales Growth"

- Huons N: Sales KRW 71.7bill, OP KRW 1.0bill
- Sales & Profitability Improved Post Spin-off Merger
- Huons Life Science: Sales KRW 25.1bill, OP KRW 0.17bill - Turned Profitable YoY
- Pangen Biotech: Sales KRW 13.4bill, OP KRW 1.5bill
- One-time Operating Loss in Q4
- BioRosette: Acquired in Nov. '25


Quarterly Standalone P&L

[Unit: billion KRW, %]


	4Q24	1Q25	2Q25	3Q25	4Q25
Sales	131.3	131.6	132.1	125.2	132.2 (YoY +0.6%, QoQ +5.6%)
OP	11.5	12.8	12.2	9.5	11.6 (YoY +1.1%, QoQ +21.6%)
OP Margin	8.7%	9.8%	9.3%	7.6%	8.8%
NP	8.4	12.3	7.1	7.6	12.4 (YoY +46.4%, QoQ 62.8%)
NP Margin	6.4%	9.3%	5.4%	6.1%	9.4%

Subsidiaries' Individual Sales

[Unit: billion KRW]



Subsidiaries' Individual OP



1. Business Performance_Cost Analysis


- Q4 Cost of Sales KRW 95.6bill (YoY +5.4%p, QoQ +2.7%p) / SG&A KRW 59.7bill (YoY -3.8%p, QoQ -2.2%p)
 - ✓ Cost Ratio Up: Higher merchandise (medical devices) sales & post-GMP approval of injectable line at Factory 2
 - ✓ SG&A Ratio Down: Cost controls on service fees & advertising offset increased R&D spend

Cost Analysis


[Unit: billion KRW, %]

Category	4Q24		1Q25		2Q25		3Q25		4Q25		YoY	QoQ
Sales	146.6		145.8		156.0		153.7		165.2		+12.5%	+5.9%
Costs of sales	77.0	52.5%	75.3	51.7%	82.7	53.0%	84.9	55.2%	95.6	57.9%	+5.4%p	+2.7%p
SG&A Expenses	58.7	40.0%	57.7	39.5%	60.2	38.6%	59.0	38.4%	59.7	36.2%	-3.8%p	-2.2%p
Category	Amount	% of Sales	Amount	% of Sales	Amount	% of Sales	Amount	% of Sales	Amount	% of Sales ²⁾	YoY	QoQ
Labor ¹⁾	8.3	5.6%	8.7	6.0%	8.3	5.3%	8.1	5.3%	8.3	5.0%	+0.7%	+2.3%
Advertising	3.8	2.6%	3.1	2.1%	3.4	2.2%	2.9	1.9%	2.7	1.6%	-29.4%	-7.8%
Commissions	11.1	7.6%	8.8	6.0%	10.5	6.7%	8.4	5.5%	9.3	5.6%	-16.7%	+10.1%
R&D	9.6	6.5%	9.9	6.8%	9.8	6.3%	10.4	6.7%	11.8	7.1%	+23.0%	+13.9%
Others	25.9	17.6%	27.1	18.6%	28.2	18.1%	29.1	19.0%	27.6	16.7%	+6.8%	-5.2%

Cost of sales/SG&A Ratio



Performance by Business Divisions



1) Revenue of subsidiaries (Huons N, Huons Life Science, Pangen Biotech, BioRosette) including consolidation adjustments

* Pangen Biotech consolidated from Jun. '25 / BioRosette consolidated from Nov. '25

4Q25 Review

ETC Q4 Sales KRW **72.0bill** (YoY ▲3.1%, QoQ ▲2.9%)

- Steady growth in anesthetics / Increased eye drops sales
- North America injectable exports KRW 4.3bill (YoY +41.0%, QoQ -17.1%)
- Other countries exports KRW 9.8bill (YoY -6.0%, QoQ +33.4%), continued growth in exports to Middle East and Japan

Beauty & Wellbeing Q4 Sales KRW **41.5bill** (YoY ▼3.5%, QoQ ▲17.8%)

- Sales excl. Health Functional Food division KRW 41.0bill (YoY +33.2%, QoQ +18.2%)
- Steady growth in wellbeing/obesity/pain medication sales KRW 21.9bill (YoY +3.7%, QoQ +2.0%)

CMO Q4 Sales KRW **18.6bill** (YoY ▲2.1%, QoQ ▼6.5%)

- Eye drop sales KRW 8.1bill (YoY +17.9%, QoQ +14.8%), Sales increase driven by recovery in eye drops line operating days
- Other pharmaceuticals KRW 10.5bill (YoY -7.4%, QoQ -18.2%)





Subsidiaries Q4 Sales KRW **34.3bill** (YoY ▲92.3%, QoQ ▲16.0%)

- Huons N Q4 Sales KRW 21.9bill (YoY +76%, QoQ +13%)
 - Health functional food export expansion (Q4 exports KRW 3.5bill, YoY +217%, QoQ +57%)
- Huons Life Science Q4 Sales KRW 6.8bill (YoY +25%, QoQ +9%)
- Pangen Biotech Q4 Sales KRW 2.5bill (QoQ -38.4%)
 - Decline in EPO pharmaceutical exports (Q4 exports KRW 1.16bill, QoQ -16%)

2. Performance by Business Divisions


- Balanced Growth Driven by a Diversified Business Portfolio

[Unit: billion KRW]



3. Business Update_Expanding Export Portfolio to Capture Global Markets

- Consolidated Annual Export Sales Reaches All-Time High KRW 64.3bill (YoY +24%)
 - U.S.: Injectable exports KRW 18.4bill (YoY +52.3%) / New CMC eye drops exports / Higher health functional food exports
 - Other Countries: Steady growth in Middle East & Japan / Japan dental anesthetic sales growth expected in '26




FDA

Listing of lidocaine drugs on the FDA-designated shortage list is creating stable market demand in the U.S.



Export Sales Trend

[Unit: billion KRW, Consolidated]



'25 Huons Exports KRW **49.7bill** (YoY ▲14.9%)
 - Injectables KRW 43.0bill (YoY +9.9%) / Other pharma KRW 6.7bill (YoY +89.1%)


'25 Health Functional Food Exports KRW **11.0bill** (YoY ▲33.9%)
 - Diversified North America distribution & expanded export markets

'25 EPO Pharmaceutical Exports KRW **3.8bill**¹⁾
 - Stable growth in existing licensed markets (Türkiye, Saudi Arabia, Malaysia, etc.)

1) Export revenue for Jun. ~ Dec. '25

- Factory 2 Injectable Line Commences Full Operations Following GMP Approval
 - ✓ Injectable Line: Additional capacity secured via Factory 2 GMP approval / Vial line full operations to begin in '26
 - ✓ Eye Drop Line: Higher Factory 2 utilization & continued growth on expanding exports

Eye drop sales¹⁾




Production performance status

(Unit: million units, billion KRW, %)

Classification	Dosage Form	CAPA ²⁾		Output (unit : million)		Utilization rate (annualized)		Production performance (amount)	
		2024	2025	2024	2025	2024	2025	2024	2025
1 st Factory	Injectable	260	235	254	247	98%	105%	130.5	125.0
	Ampoule	57	64	69	80	122%	126%	41.6	48.0
	Vial	25	23	31	25	122%	109%	44.1	33.5
	Cartridge	138	109	127	120	92%	109%	35.4	35.3
	Plastic	40	38	27	22	67%	56%	9.3	8.2
	Eye Drop	340	274	348	243	102%	89%	42.4	35.1
	Oral Formulation	821	1,181	798	1,067	97%	90%	133.5	189.0
2 nd Factory	Injectable (Vial)	Injectable line GMP approved Aug. '25 / Vial line operations to begin in '26							
	Injectable (Cartridge)								
	Eye Drops	154	156	84	140	55%	89%	6.5	13.2

Huons 2026 Target Consolidated Sales KRW 646.2bill (YoY ▲4.1%)



1) Pangen Biotech consolidated into P&L from Jun. '25
/ BioRosette consolidated from Nov. '25

2026 Key Business Strategies

Domestic Business (ETC / Wellbeing Pharmaceuticals)

- Stable growth in domestic pharmaceutical business
- Sales expansion and earnings improvement from Factory 2 injectable line full operations in '26
- Strengthen R&D investment and pipeline (dry eye, obesity, etc.) to identify mid-to-long term growth drivers

Overseas Business (Injectables / Other Pharmaceuticals)

- Growth strategy centered on global exports of injectables and eye drops
- U.S. FDA ANDA filing for dental local anesthetic
- Export growth of lidocaine & epinephrine anesthetics to Japan

CMO (Eye Drops / Other Pharmaceuticals)

- Earnings improvement through higher Factory 2 eye drop line utilization^W
- Enhanced manufacturing capabilities and product profitability via advanced aseptic GMP system compliance

Subsidiaries (Huons N / Huons Life Science / Pangen Biotech / BioRosette)

- Huons N:

- 1) Expand export portfolio and grow sales volume via entry into major U.S. distributors
- 2) Expand MFDS individually recognized ingredient product lineup and overseas-certified export items

- HuonsLifeScience:

- 1) Cost ratio improvement by converting contracted products to in-house production

- Pangen Biotech:

- 1) Expand biosimilar (EPO) product approvals into new markets (Peru, Iraq, etc.) and grow sales in existing markets
- 2) CMO Sales growth and royalty income growth expected via CDO

2025 Year-End Cash Dividend

Dividend Type	Cash Dividend
DPS	KRW 200
Total Dividend	KRW 2,330,352,200
Record Date	April 3, 2026
Payment Date	April 22, 2026
Note	Capital Reduction Dividend ¹⁾ (Tax-exempt)


* 2025 year-end dividend subject to final approval at the Annual General Meeting

Mid-to-Long Term Dividend Policy

	New Mid-to-Long Term Dividend Policy
Period	3 Years (2026~2028)
Dividend Standard	Dividend per Share
Dividend Type	Cash Dividend (Quarterly + Year-end), 4 Times Per Year
Dividend Source	Tax-exempt Capital Reduction Dividend (Amount transferred from capital surplus to retained earnings)
Target Dividend	1) 2026 Quarterly Dividend KRW 200, Annual Total KRW 800 2) Annual DPS to increase by 5%~30% thereafter

Dividend History

H1 Dividend KRW 1.16bill / Q3 Dividend KRW 6.64bill /
Year-end Dividend KRW 2.33bill



의약품		Indication	Preclinical	Clinical			Approval	Etc.
				Phase 1	Phase 2	Phase 3		
	Novel Drug	Dry Eye			HUC1-394		Domestic Phase 2 IND filed	
		NSCLC ¹⁾	HUC1-733 (TRX-211)					Licensed from Therapex
		Obesity (Oral)	HUC1-622					Lead compound stage
		Obesity (Oral)	HUCi-670					Hit compound stage
		Fibrotic Disease	HUC1-626					Lead compound stage
		Obesity (Oral)	HUCi-745					Hit compound stage
	Improved New Drug / Data Submission Drug	Glaucoma				HUC3-637		
		Obesity (GLP-1)		HUC2-676				Domestic Phase 1 IND approved / NDA filing planned post Phase 1
		Hypertension	HUC2-694					
Health Functional Food		Indication	Preclinical	Human Trial	MFDS Individual Recognition Filing	Approval	Etc.	
 Huons <i>IV</i>	Health Functional Food (Individual Recognition)	Prostate Health			HFN2-007		Individual recognition filed & under review	
		Body Fat (Anti-obesity)		HFN2-008			Human trial successful	
		Fatigue Relief / Exercise Performance		HFN2-016,023			Human trial successful	
		Body Fat (Anti-obesity)			HFN2-027		Individual recognition filed	

Statement of Financial Position

[Unit: mil KRW]

Classification	4Q24	1Q25	2Q25	3Q25	4Q25
Assets	606,285	604,864	635,532	644,238	678,620
Current assets	256,909	258,171	276,394	285,727	289,636
Cash etc.*	68,874	67,174	65,367	74,222	66,170
Accounts receivable	95,322	90,849	101,518	105,020	114,499
Inventory Asset	76,253	81,787	95,578	91,840	94,366
Non-current assets	349,376	346,693	359,138	358,510	388,984
Property, plant and equipment	242,671	239,801	249,583	250,654	263,882
Liabilities	255,690	248,676	247,159	248,983	265,436
Current liabilities	153,496	159,761	163,497	156,735	170,773
Accounts payable	18,257	19,861	20,813	20,018	23,741
Short-term borrowings**	77,667	81,367	81,367	81,367	92,141
Non-current liabilities	102,195	88,915	83,662	92,248	94,663
Long-term borrowings	89,200	76,333	68,445	80,090	76,677
Equity	350,595	356,188	388,373	395,254	413,184
Equity attributable to owners of parent	345,971	351,519	361,602	368,181	374,246
Retained earnings	269,458	327,920	339,500	346,635	351,195
Non-controlling interests	4,624	4,669	26,771	27,073	38,938
Stability Indicator					
Current ratio	167%	162%	169%	182%	170%
Debt to equity ratio	73%	70%	64%	63%	64%
Borrowing ratio	48%	44%	39%	41%	41%
Net debt ratio	28%	25%	22%	22%	25%
Interest coverage ratio	882%	684%	1017%	1017%	618%

*Cash etc. = Cash & Cash Equivalent + Short-term Financial Instruments

** Including current portion of long-term debt

*** Figures accumulated for 4 quarters

Statements of Comprehensive Income

[Unit: mil KRW]

Classification	4Q24	1Q25	2Q25	3Q25	4Q25
Sales	146,623	145,836	156,030	153,717	165,185
Cost of sales	76,961	75,339	82,723	84,872	95,620
Gross profit	69,662	70,497	73,307	68,845	69,565
SG&A expenses	58,651	57,651	60,250	58,971	59,717
Operating Profit	11,011	12,845	13,057	9,873	9,848
Gains/Losses on investments in associates	127	289	271	-189	-59
Other gains/losses	-4,817	-583	1,957	-295	1,129
Profit before tax	6,321	12,551	15,285	9,389	10,917
Income tax expense	2,397	202	3,438	1,163	1,697
Net Profit	3,924	12,349	11,848	8,226	9,220
Profit, attributable to owners	3,940	12,306	11,584	7,923	10,241
Profit, attributable to non-controlling interests	-16	43	264	302	-1,021
A Profitability Indicator					
Operating profit ratio	7.5%	8.8%	8.4%	6.4%	6.0%
EBITDA Margin	11.3%	12.6%	12.1%	6.9%	11.4%
Net profit ratio	2.7%	8.5%	7.6%	5.4%	5.6%
ROE***	8.5%	9.1%	9.7%	9.8%	10.9%
Sales/Asset***	103%	103%	99%	98%	97%
Leverage	173%	170%	164%	163%	164%

Thank you